Cisplatin-ineligible and chemotherapy-ineligible patients should be the focus of new drug development in patients with advanced bladder cancer.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Clinical Genitourinary Cancer

• Publication date

  2014-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.clgc.2013.11.016PMID 24355418
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer.

  2013cited by this paper
• Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma.

  2013cited by this paper
• Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986.

  2012cited by this paper
• Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community.

  2012cited by this paper
• Prevalence and characteristics of patients with metastatic cancer who receive no anticancer therapy

  2012cited by this paper
• Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma.

  2012cited by this paper
• A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy.

  2011cited by this paper
• Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.

  2011cited by this paper
• Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.

  2011cited by this paper
• First-line systemic therapy trials for advanced transitional-cell carcinoma of the urothelium: should we stop separating cisplatin-eligible and -ineligible patients?

  2010cited by this paper
• Impact of renal impairment on eligibility for adjuvant cisplatin‐based chemotherapy in patients with urothelial carcinoma of the bladder

  2006cited by this paper
• Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.

  2006cited by this paper
• Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.

  2006cited by this paper
• Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer

  2005cited by this paper
• A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer

  2004cited by this paper
• Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.

  2000cited by this paper
• Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

  1997cited by this paper
• A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

  1992cited by this paper
• A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.

  1990cited by this paper

• Patients with Metastatic or Locally Advanced Bladder Cancer Not Undergoing Systemic Oncological Treatment—Characteristics and Long-Term Outcome in a Single-Center Danish Cohort

  2025cites this paper
• Effectiveness and safety of PD-1/L1 inhibitors as first-line therapy for patients with advanced or metastatic urothelial carcinoma who are ineligible for platinum-based chemotherapy: a meta-analysis

  2025cites this paper
• Jolkinolide B synergistically potentiates the antitumor activity of GPX4 inhibitors via inhibiting TrxR1 in cisplatin-resistant bladder cancer cells.

  2024cites this paper
• Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum‐containing chemotherapy: Post hoc analysis of KEYNOTE‐052 and LEAP‐011

  2024cites this paper
• SPHK1 promotes bladder cancer metastasis via PD-L2/c-Src/FAK signaling cascade

  2024cites this paper
• Expression of transferrin receptor/TFRC protein in bladder cancer cell T24 and its role in inducing iron death in bladder cancer.

  2024cites this paper
• Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial.

  2023cites this paper
• Physician reported treatment patterns and outcomes in metastatic bladder cancer in the USA: the CancerMPact® Survey 2020.

  2023cites this paper
• Management of Advanced Urothelial Carcinoma in Older and Frail Patients: Have Novel Treatment Approaches Improved Their Care?

  2022cites this paper
• The Impact of Neutrophil-to-Lymphocyte Ratio after Two Courses of Pembrolizumab for Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma

  2022cites this paper
• Clinical evidence and insights supporting the use of avelumab first‐line maintenance treatment in patients with advanced urothelial carcinoma in the Asia‐Pacific region

  2022cites this paper
• Dramatic Responses of Recurrent Upper Urinary Tract Urothelial Carcinoma Harboring FGFR3 and TP53 Activating Mutations to Pembrolizumab in Combination with Erdafitinib: A Case Report

  2021cites this paper
• Immuno-oncology therapy in metastatic bladder cancer: a systematic review and network meta-analysis.

  2021cites this paper
• Jolkinolide B sensitizes bladder cancer to mTOR inhibitors via dual inhibition of Akt signaling and autophagy.

  2021cites this paper
• Efficacy and safety of pembrolizumab for older patients with chemoresistant urothelial carcinoma assessed using propensity score matching.

  2021cites this paper
• Jolkinolide B targets thioredoxin and glutathione systems to induce ROS-mediated paraptosis and apoptosis in bladder cancer cells.

  2021cites this paper
• Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis.

  2021cites this paper
• Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma

  2020cites this paper
• Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status

  2020cites this paper
• Immune checkpoint inhibition in muscle-invasive and locally advanced bladder cancer.

  2020cites this paper
• Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer.

  2020cites this paper
• From clinical trials to clinical use of checkpoint inhibitors for patients with metastatic urothelial cancer.

  2020cites this paper
• Restricted mean survival time as outcome measure in advanced urothelial bladder cancer: analysis of 4 clinical studies.

  2020cites this paper
• Comparative Study of the Safety and Efficacy of First-Line Cisplatin and Carboplatin Chemotherapy in Elderly Patients with Metastatic Urothelial Carcinoma

  2019cites this paper
• Management of metastatic bladder cancer.

  2019cites this paper
• Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential

  2019cites this paper
• Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy.

  2019cites this paper
• Brazilian consensus in muscle-invasive and metastatic urothelial carcinoma

  2019cites this paper
• Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer

  2019cites this paper
• Pembrolizumab in the treatment of locally advanced or metastatic urothelial carcinoma: clinical trial evidence and experience

  2019cites this paper
• Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition

  2018cites this paper
• Prime time for immunotherapy in advanced urothelial cancer

  2018cites this paper
• First‐line checkpoint inhibitors in PD‐L1‐positive patients with advanced urothelial carcinoma

  2018cites this paper
• Survival Rates and Health Care Costs for Patients With Advanced Bladder Cancer Treated and Untreated With Chemotherapy

  2018cites this paper
• Immuntherapie beim lokal fortgeschrittenen und metastasierten Harnblasenkarzinom

  2018cites this paper
• Systemic Therapy for Advanced Urothelial Carcinoma: Current Standards and Treatment Considerations.

  2018cites this paper
• Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United States

  2018cites this paper
• Treatment Patterns and Outcomes in Stage IV Bladder Cancer in a Community Oncology Setting: 2008‐2015

  2018cites this paper
• First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.

  2017cites this paper
• Accelerating Early Access to Immunotherapies for Advanced Urothelial Carcinoma

  2017cites this paper
• Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.

  2017cites this paper
• Emerging first line treatment options for bladder cancer: a review of phase II and III therapies in the pipeline

  2017cites this paper
• Atezolizumab in invasive and metastatic urothelial carcinoma

  2017cites this paper
• Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

  2017cites this paper
• Bladder cancer in the elderly patient: challenges and solutions

  2015cites this paper
• Bladder cancer in the elderly patient: challenges and solutions

  2015cites this paper
• Bladder cancer in the elderly patient: challenges and solutions

  2015cites this paper
• Docetaxel for the treatment of bladder cancer

  2015cites this paper
• Bladder cancer in the elderly patient: challenges and solutions

  2015cites this paper
• Future directions and targeted therapies in bladder cancer.

  2015cites this paper